Status:
COMPLETED
Insulin Secretion in Diabetes Before and After Glycemic Control
Lead Sponsor:
US Department of Veterans Affairs
Conditions:
Diabetes
Hyperglycemia
Eligibility:
All Genders
30-65 years
Phase:
NA
Brief Summary
The objective of this project is to understand defects in insulin secretion that contribute to abnormal glucose metabolism in patients with diabetes. In particular the effects of signals released from...
Detailed Description
The objective of this project is to understand defects in insulin secretion that contribute to abnormal glucose metabolism in patients with diabetes. Diabetes is a major problem for patients receiving...
Eligibility Criteria
Inclusion
- Aim 1:
- (non-diabetics)
- male/female 30-65 yrs old,
- free of active medical disease,
- no history of diabetes.
- (diabetics)
- HbA1c=6.5-8.5,
- treated with metformin, a sulfonylurea, or combination,
- Stable body wt with BMI 28-40.
- Aim 2: Same as above
- Aim 3: Diabetic with HgA1c 8.0-9.5
Exclusion
- Aim 1: For both groups: no history of: pancreatitis, cardiac, gastrointestinal, renal or liver disease.
- Aim 2: Same as above
- Aim 3: Same as above, plus a diagnosis of incipient diabetic nephropathy severe nonproliferative, or proliferative retinopathy.
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2012
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00469833
Start Date
April 1 2008
End Date
September 1 2012
Last Update
January 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Medical Center, Cincinnati
Cincinnati, Ohio, United States, 45220